Laferon-FarmBiotek lyophilisate for solution for injections 1 mln IU №10 vial

Description

Laferon 1 mln Composition
active substance: recombinant human interferon alpha-2b;

1 bottle contains recombinant human interferon alpha-2b 1 million, 3 million, 5 million, 6 million, 9 million or 18 million IU;

excipients: sodium chloride, dextran 70, potassium dihydrogen phosphate, sodium hydrogen phosphate anhydrous.

Laferon 1 mln Dosage form

Lyophilisate for solution for injection.

Basic physical and chemical properties: lyophilized powder or porous white mass, hygroscopic.

Laferon 1 mln Pharmacotherapeutic group

Immunostimulants

Interferon alpha-2b. ATX code L03A B05.

Laferon 1 mln Pharmacological properties

Pharmacodynamics

Recombinant human interferon alpha-2b is a highly purified, water-soluble protein with a molecular weight of 19,300 daltons.

Laferon-PharmBiotek®, like natural leukocyte interferon, has three main types of biological activity: immunomodulatory, antiviral and antitumor.

The mechanism of action of Laferon-PharmBiotek® is based on the fact that interferon, binding to the corresponding receptors of the body’s cells, induces a complex of intracellular mechanisms leading to the appearance of enzymes that prevent viral replication, increase the phagocytic activity of macrophages, and inhibit the specific cytotoxicity of lymphocytes to target cells proliferation of metastatic cells.

Pharmacokinetics

No data available

Clinical characteristics

Indications
Laferon-PharmBiotek® is used in complex therapy for:

acute and chronic viral hepatitis B (moderate and severe forms);
chronic hepatitis C;
acute viral, bacterial and mixed infections (including acute respiratory viral infection in children, including newborns, acute diarrheal syndrome in newborns, acute intestinal infections in young children with symptoms of hypocoagulation);
acute and chronic septic diseases of a viral and bacterial nature, including disseminated forms of acute and chronic sepsis;
herpetic infections of various localization: shingles, multiple skin herpetic eruptions; genital herpes infection; herpetic keratoconjunctivitis and keratouveitis, acute herpetic stomatitis in children;
chronic urogenital chlamydia;
lesions of the nervous system with mono- and polyradicular pain syndromes;
multiple sclerosis;
papillomatosis of the larynx;
melanoma of the skin and eyes; cancer of the kidney, bladder, ovary, breast; Kaposi’s sarcoma, multiple myeloma; chronic myeloid leukemia, hairy cell leukemia, non-Hodgkin malignant lymphomas, basal cell carcinoma; T-cell lymphoma of the skin (fungal mycosis).

Laferon 1 mln Contraindications
Hypersensitivity to interferon alfa-2b or other components of the drug;
severe diseases of the cardiovascular system (including heart failure in the stage of decompensation, recent myocardial infarction, severe arrhythmia);
severe dysfunction of the kidneys or liver, including in connection with metastases;
epilepsy and / or dysfunction of the central nervous system (including functional);
chronic hepatitis with decompensated liver cirrhosis;
chronic hepatitis in patients who are undergoing or have recently received treatment with immunosuppressive drugs other than a short course of corticosteroid therapy;
a history of autoimmune hepatitis or autoimmune disease; transplant recipients after immunosuppressive therapy;
a pre-existing thyroid disorder that is not controlled by conventional therapies;
the presence of severe visceral disorders in patients with Kaposi’s sarcoma;
psoriasis, sarcoidosis, if the potential benefit does not outweigh the potential risk;
combination of Laferon-PharmBiotek® with telbivudine;
the period of pregnancy (the safety of using the drug during pregnancy has not been established).